Living with Atopic Dermatitis (EU) 2019 report

Living with Atopic Dermatitis (AD) is a new quantitative study conducted amongst 403 adults living with the disease and 141 caregivers of children with AD in France, Germany, Italy, Spain and UK. 

AD is a common, chronic inflammatory skin disease that is characterised by intense itching and recurrent eczematous lesions and is estimated to affect 20% of children and 3% of adults worldwide. Until a few years ago, AD treatments were mainly limited to topical corticosteroids and systemic immunosuppressants, however a greater understanding of how AD develops has lead to the launch of new treatments (PDE-4 inhibitor, dupilumab) as well as a more robust pipeline.

The report enables pharmaceutical companies developing products in AD to gain a deeper understanding of how patients come to be diagnosed with AD and how it impacts their day-to-day lives physically, emotionally and socially. It also explores patient attitudes and perceptions towards treatment and the healthcare professionals managing their condition as well as identifying the types of support patients seek at key stages of their journey.

Head of Living with, Mariel Metcalfe commented, “Atopic Dermatitis can exert a major physical and emotional burden not only on the patient but also their caregivers. This report will provide comprehensive, quantitative insights into patient behaviours and perceptions, as well as their feelings and unmet needs at key stages of their journey living with AD.”

To discover more, download our new interactive infographic to unlock key insights from various Living With reports to reveal patient behaviours, attitudes and unmet needs at different stages of their chronic disease journey. Download the infographic »

Find out more about our Living With reports »